Zinc oxide calcium silicate composite attenuates acute tramadol toxicity in mice

Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced seizure cases. Although, diazepam clears these seizures, the risk of central respiratory depression cannot be overlooked. Henceforth, three adsorbi...

Full description

Saved in:
Bibliographic Details
Published inBMC pharmacology & toxicology Vol. 24; no. 1; p. 9
Main Authors ElShebiney, Shaimaa A, Elgohary, Rania, Kenawy, Sayed H, El-Bassyouni, Gehan T, Hamzawy, Esmat M A
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 09.02.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced seizure cases. Although, diazepam clears these seizures, the risk of central respiratory depression cannot be overlooked. Henceforth, three adsorbing composites were examined in a tramadol acute intoxication mouse model. Calcium Silicate (Wollastonite) either non-doped or wet doped with iron oxide (3%Fe O ) or zinc oxide (30% ZnO) were prepared. The composites' adsorption capacity for tramadol was determined in vitro. Tramadol intoxication was induced in Swiss albino mice by a parenteral dose of 120 mg/kg. Proposed treatments were administered within 1 min at 5 increasing doses, i.p. The next 30 min, seizures were monitored as an intoxication symptom. Plasma tramadol concentration was recorded after two hours of administration. The 3% Fe O -containing composite (CSFe3), was found to be composed of mainly wollastonite with very little alpha-hematite. On the other hand, hardystonite and wellimite were developed in the 30%ZnO-containing composite (CSZn3). Micro-round and irregular nano-sized microstructures were established (The particle size of CS was 56 nm, CSFe3 was 49 nm, and CSZn3 was 42 nm). The CSZn3 adsorption capacity reached 1497 mg of tramadol for each gram. Tramadol concentration was reduced in plasma and seizures were inhibited after its administration to mice at three doses. The calcium silicate composite doped with ZnO presented a good resolution of tramadol-induced seizures accompanied by detoxification of blood, indicating its potential for application in such cases. Further studies are required.
AbstractList BACKGROUNDSeizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced seizure cases. Although, diazepam clears these seizures, the risk of central respiratory depression cannot be overlooked. Henceforth, three adsorbing composites were examined in a tramadol acute intoxication mouse model. METHODSCalcium Silicate (Wollastonite) either non-doped or wet doped with iron oxide (3%Fe2O3) or zinc oxide (30% ZnO) were prepared. The composites' adsorption capacity for tramadol was determined in vitro. Tramadol intoxication was induced in Swiss albino mice by a parenteral dose of 120 mg/kg. Proposed treatments were administered within 1 min at 5 increasing doses, i.p. The next 30 min, seizures were monitored as an intoxication symptom. Plasma tramadol concentration was recorded after two hours of administration. RESULTSThe 3% Fe2O3-containing composite (CSFe3), was found to be composed of mainly wollastonite with very little alpha-hematite. On the other hand, hardystonite and wellimite were developed in the 30%ZnO-containing composite (CSZn3). Micro-round and irregular nano-sized microstructures were established (The particle size of CS was 56 nm, CSFe3 was 49 nm, and CSZn3 was 42 nm). The CSZn3 adsorption capacity reached 1497 mg of tramadol for each gram. Tramadol concentration was reduced in plasma and seizures were inhibited after its administration to mice at three doses. CONCLUSIONThe calcium silicate composite doped with ZnO presented a good resolution of tramadol-induced seizures accompanied by detoxification of blood, indicating its potential for application in such cases. Further studies are required.
Abstract Background Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced seizure cases. Although, diazepam clears these seizures, the risk of central respiratory depression cannot be overlooked. Henceforth, three adsorbing composites were examined in a tramadol acute intoxication mouse model. Methods Calcium Silicate (Wollastonite) either non-doped or wet doped with iron oxide (3%Fe2O3) or zinc oxide (30% ZnO) were prepared. The composites’ adsorption capacity for tramadol was determined in vitro. Tramadol intoxication was induced in Swiss albino mice by a parenteral dose of 120 mg/kg. Proposed treatments were administered within 1 min at 5 increasing doses, i.p. The next 30 min, seizures were monitored as an intoxication symptom. Plasma tramadol concentration was recorded after two hours of administration. Results The 3% Fe2O3-containing composite (CSFe3), was found to be composed of mainly wollastonite with very little alpha–hematite. On the other hand, hardystonite and wellimite were developed in the 30%ZnO-containing composite (CSZn3). Micro-round and irregular nano-sized microstructures were established (The particle size of CS was 56 nm, CSFe3 was 49 nm, and CSZn3 was 42 nm). The CSZn3 adsorption capacity reached 1497 mg of tramadol for each gram. Tramadol concentration was reduced in plasma and seizures were inhibited after its administration to mice at three doses. Conclusion The calcium silicate composite doped with ZnO presented a good resolution of tramadol-induced seizures accompanied by detoxification of blood, indicating its potential for application in such cases. Further studies are required.
Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced seizure cases. Although, diazepam clears these seizures, the risk of central respiratory depression cannot be overlooked. Henceforth, three adsorbing composites were examined in a tramadol acute intoxication mouse model. Calcium Silicate (Wollastonite) either non-doped or wet doped with iron oxide (3%Fe O ) or zinc oxide (30% ZnO) were prepared. The composites' adsorption capacity for tramadol was determined in vitro. Tramadol intoxication was induced in Swiss albino mice by a parenteral dose of 120 mg/kg. Proposed treatments were administered within 1 min at 5 increasing doses, i.p. The next 30 min, seizures were monitored as an intoxication symptom. Plasma tramadol concentration was recorded after two hours of administration. The 3% Fe O -containing composite (CSFe3), was found to be composed of mainly wollastonite with very little alpha-hematite. On the other hand, hardystonite and wellimite were developed in the 30%ZnO-containing composite (CSZn3). Micro-round and irregular nano-sized microstructures were established (The particle size of CS was 56 nm, CSFe3 was 49 nm, and CSZn3 was 42 nm). The CSZn3 adsorption capacity reached 1497 mg of tramadol for each gram. Tramadol concentration was reduced in plasma and seizures were inhibited after its administration to mice at three doses. The calcium silicate composite doped with ZnO presented a good resolution of tramadol-induced seizures accompanied by detoxification of blood, indicating its potential for application in such cases. Further studies are required.
Background Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced seizure cases. Although, diazepam clears these seizures, the risk of central respiratory depression cannot be overlooked. Henceforth, three adsorbing composites were examined in a tramadol acute intoxication mouse model. Methods Calcium Silicate (Wollastonite) either non-doped or wet doped with iron oxide (3%Fe.sub.2O.sub.3) or zinc oxide (30% ZnO) were prepared. The composites' adsorption capacity for tramadol was determined in vitro. Tramadol intoxication was induced in Swiss albino mice by a parenteral dose of 120 mg/kg. Proposed treatments were administered within 1 min at 5 increasing doses, i.p. The next 30 min, seizures were monitored as an intoxication symptom. Plasma tramadol concentration was recorded after two hours of administration. Results The 3% Fe.sub.2O.sub.3-containing composite (CSFe3), was found to be composed of mainly wollastonite with very little alpha-hematite. On the other hand, hardystonite and wellimite were developed in the 30%ZnO-containing composite (CSZn3). Micro-round and irregular nano-sized microstructures were established (The particle size of CS was 56 nm, CSFe3 was 49 nm, and CSZn3 was 42 nm). The CSZn3 adsorption capacity reached 1497 mg of tramadol for each gram. Tramadol concentration was reduced in plasma and seizures were inhibited after its administration to mice at three doses. Conclusion The calcium silicate composite doped with ZnO presented a good resolution of tramadol-induced seizures accompanied by detoxification of blood, indicating its potential for application in such cases. Further studies are required. Keywords: Adsorption, Antidote, Silicate phases, Nano-microstructure, Toxicity management, Wollastonite
Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced seizure cases. Although, diazepam clears these seizures, the risk of central respiratory depression cannot be overlooked. Henceforth, three adsorbing composites were examined in a tramadol acute intoxication mouse model. Calcium Silicate (Wollastonite) either non-doped or wet doped with iron oxide (3%Fe.sub.2O.sub.3) or zinc oxide (30% ZnO) were prepared. The composites' adsorption capacity for tramadol was determined in vitro. Tramadol intoxication was induced in Swiss albino mice by a parenteral dose of 120 mg/kg. Proposed treatments were administered within 1 min at 5 increasing doses, i.p. The next 30 min, seizures were monitored as an intoxication symptom. Plasma tramadol concentration was recorded after two hours of administration. The 3% Fe.sub.2O.sub.3-containing composite (CSFe3), was found to be composed of mainly wollastonite with very little alpha-hematite. On the other hand, hardystonite and wellimite were developed in the 30%ZnO-containing composite (CSZn3). Micro-round and irregular nano-sized microstructures were established (The particle size of CS was 56 nm, CSFe3 was 49 nm, and CSZn3 was 42 nm). The CSZn3 adsorption capacity reached 1497 mg of tramadol for each gram. Tramadol concentration was reduced in plasma and seizures were inhibited after its administration to mice at three doses. The calcium silicate composite doped with ZnO presented a good resolution of tramadol-induced seizures accompanied by detoxification of blood, indicating its potential for application in such cases. Further studies are required.
ArticleNumber 9
Audience General
Author Kenawy, Sayed H
Elgohary, Rania
Hamzawy, Esmat M A
El-Bassyouni, Gehan T
ElShebiney, Shaimaa A
Author_xml – sequence: 1
  givenname: Shaimaa A
  surname: ElShebiney
  fullname: ElShebiney, Shaimaa A
  email: sa.elshebiney@nrc.sci.eg
  organization: Narcotics, Ergogenics, and Poisons Department, National Research Centre, 33-El-Buhouth St., 12622, Dokki, Giza, Egypt. sa.elshebiney@nrc.sci.eg
– sequence: 2
  givenname: Rania
  surname: Elgohary
  fullname: Elgohary, Rania
  organization: Narcotics, Ergogenics, and Poisons Department, National Research Centre, 33-El-Buhouth St., 12622, Dokki, Giza, Egypt
– sequence: 3
  givenname: Sayed H
  surname: Kenawy
  fullname: Kenawy, Sayed H
  organization: Refractories, Ceramics and Building Materials Department, National Research Centre, 33 El Buhouth St, Dokki, Giza, 12622, Egypt
– sequence: 4
  givenname: Gehan T
  surname: El-Bassyouni
  fullname: El-Bassyouni, Gehan T
  organization: Refractories, Ceramics and Building Materials Department, National Research Centre, 33 El Buhouth St, Dokki, Giza, 12622, Egypt
– sequence: 5
  givenname: Esmat M A
  surname: Hamzawy
  fullname: Hamzawy, Esmat M A
  organization: Glass Research Department, National Research Centre, 33 El Buhouth St, Dokki, Giza, 12622, Egypt
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36759887$$D View this record in MEDLINE/PubMed
BookMark eNptUl1rFDEUHaRia-0f8EEGBPFlar4_XoRS1BYK-qAvvoRsktnNMpOsk0yx_9673bbuislDLifnnJB7z8vmKOUUmuY1RucYK_GhMEQF6hChHUKCyQ49a04I4qgTHOOjvfq4OStljWBJqRQnL5pjKiTXSsmT5tvPmFybf0cfWmcHF-exLXGIzlYA8rjJJUJlaw1pBqy01s0A1MmO1uehraB1sd61MbVjdOFV87y3QwlnD-dp8-Pzp--XV93N1y_Xlxc3neOa1c73OHgcFObaSU8XljKtmBZEOEUxIlwshMcyMETCwlnVO-p84N5RhAJo6GlzvfP12a7NZoqjne5MttHcA3laGjvV6IZgLPKOE617zTjDmlmO2YJy5GzPsaAUvD7uvDbzYgzehQTfGw5MD29SXJllvjVaYyKoAoP3DwZT_jWHUs0YiwvDYFPIczFESi4wY4ID9e0_1HWepwSt2rJgQkhJ8pe1tPCBmPoM77qtqbmQVHCYPdXAOv8PC7YPMArISx8BPxC82xOsgh3qquRhrjGnckgkO6KbcilT6J-agZHZ5s_s8mcgf-Y-fwaB6M1-G58kj2mjfwD-odVG
CitedBy_id crossref_primary_10_1016_j_ceramint_2024_04_342
crossref_primary_10_1016_j_ceramint_2024_01_155
Cites_doi 10.15171/apb.2019.013
10.1002/jbm.b.34767
10.1016/j.taap.2016.09.013
10.1016/j.drugalcdep.2012.09.018
10.1006/nbdi.1997.0163
10.1248/cpb.44.1361
10.1002/jnr.23609
10.1016/j.neulet.2008.08.081
10.1007/s42411-018-0010-7
10.1007/s00401-021-02348-6
10.1515/dmpt-2017-0040
10.1136/emj.2009.083162
10.1523/JNEUROSCI.2993-07.2007
10.1177/1073858404263463
10.1007/s40501-018-0149-x
10.1177/0748233713491814
10.1016/j.bbi.2018.02.004
10.2174/1874467210666170704110146
10.1007/BF03161089
10.1016/j.eplepsyres.2015.09.008
10.1680/cc.25929
10.1016/j.ceramint.2019.04.113
10.1016/j.amjmed.2018.04.025
10.3109/15563650.2014.918627
10.36076/ppj.2015/18/395
10.1124/jpet.108.137273
10.3758/BF03193146
10.1016/S0074-7742(08)60279-2
10.1111/j.1742-7843.2012.00874.x
10.1080/08897077.2012.677752
10.1007/s10522-006-9045-7
10.1016/j.ceramint.2019.11.144
10.1592/phco.20.19.1423.34854
10.3109/15563650.2015.1036279
10.1080/15563650.2017.1401080
10.3109/00952990.2015.1014959
10.1146/annurev-med-062613-093100
10.1016/B978-0-7216-0693-4.50007-4
10.1039/c3cs35451b
10.1038/sj.bjp.0703562
10.1097/01.XME.0000449839.69324.71
10.1016/j.neuro.2020.05.002
10.1177/1759091417746521
10.1177/1091581817753607
10.1016/S0022-5347(18)31271-0
10.1080/1556365050014418
10.1016/j.ceramint.2021.11.282
10.1016/S0379-0738(03)00100-2
10.31389/jied.10
10.1172/JCI43195
10.1007/BF03161033
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7U7
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
C1K
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s40360-023-00647-0
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Toxicology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
Toxicology Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database

MEDLINE



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2050-6511
EndPage 9
ExternalDocumentID oai_doaj_org_article_a0dc5299f9454194a514b350caf51633
A736503639
10_1186_s40360_023_00647_0
36759887
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Egypt
Germany
GeographicLocations_xml – name: Egypt
– name: Germany
GrantInformation_xml – fundername: ;
GroupedDBID -A0
0R~
3V.
53G
5VS
7X7
88E
8AO
8FI
8FJ
AAFWJ
AAJSJ
ABUWG
ACGFS
ACIHN
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
ASPBG
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CUY
CVF
DIK
EBD
EBLON
EBS
ECM
EIF
EMB
EMOBN
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
MK0
M~E
NPM
OK1
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SOJ
SV3
UKHRP
W2D
AAYXX
CITATION
AFGXO
7U7
7XB
8FK
AZQEC
C1K
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c594t-df1ed1e8159c7d3ba349849626c8310256b6d17e402ebca8fc3cde5dc300e59c3
IEDL.DBID RPM
ISSN 2050-6511
IngestDate Tue Oct 22 15:15:20 EDT 2024
Tue Sep 17 21:34:31 EDT 2024
Fri Oct 25 23:46:34 EDT 2024
Thu Oct 10 21:59:13 EDT 2024
Tue Nov 19 20:52:53 EST 2024
Tue Nov 12 22:42:54 EST 2024
Tue Aug 20 22:15:04 EDT 2024
Fri Nov 22 02:15:14 EST 2024
Sat Sep 28 08:13:54 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Wollastonite
Nano-microstructure
Adsorption
Antidote
Silicate phases
Toxicity management
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c594t-df1ed1e8159c7d3ba349849626c8310256b6d17e402ebca8fc3cde5dc300e59c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912638/
PMID 36759887
PQID 2777780872
PQPubID 2028884
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_a0dc5299f9454194a514b350caf51633
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9912638
proquest_miscellaneous_2775614465
proquest_journals_2777780872
gale_infotracmisc_A736503639
gale_infotracacademiconefile_A736503639
gale_healthsolutions_A736503639
crossref_primary_10_1186_s40360_023_00647_0
pubmed_primary_36759887
PublicationCentury 2000
PublicationDate 2023-02-09
PublicationDateYYYYMMDD 2023-02-09
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-09
  day: 09
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC pharmacology & toxicology
PublicationTitleAlternate BMC Pharmacol Toxicol
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References JS Gardner (647_CR8) 2000; 20
MA Mahdy (647_CR29) 2022; 48
M Ahmadimanesh (647_CR16) 2018; 33
W Zhu (647_CR34) 2018; 69
F Clarot (647_CR37) 2003; 134
TS Zimmer (647_CR55) 2021; 142
MA El-Hadidy (647_CR7) 2014; 21
JG Thundiyil (647_CR12) 2007; 3
MA Mahdy (647_CR26) 2020; 46
C Stein (647_CR41) 2016; 67
TG Smart (647_CR47) 2004; 10
RM Shamloul (647_CR17) 2020; 79
F Faul (647_CR32) 2007; 39
KD Phelan (647_CR33) 2015; 117
E Hamdi (647_CR5) 2013; 34
M Rudy (647_CR54) 2017; 9
C Reichert (647_CR15) 2014; 52
647_CR30
647_CR31
H Potschka (647_CR42) 2000; 131
H Saidi (647_CR46) 2010; 27
R Boostani (647_CR14) 2012; 3
AD Kaye (647_CR2) 2015; 18
S Shadnia (647_CR18) 2012; 111
TM Mohamed (647_CR20) 2015; 31
NM Ryan (647_CR9) 2015; 53
C Lagard (647_CR39) 2018; 56
S Hassamal (647_CR44) 2018; 131
CJ Frederickson (647_CR48) 1989; 31
M Miura (647_CR43) 2007; 27
MM Bassiony (647_CR1) 2015; 41
A Klein (647_CR3) 2019; 1
C Lagard (647_CR38) 2016; 310
647_CR22
647_CR23
647_CR24
Y Song (647_CR51) 2008; 445
V Frazzini (647_CR53) 2006; 7
H Talaie (647_CR13) 2009; 5
D Ciubotariu (647_CR49) 2007; 111
T Alexa (647_CR50) 2015; 93
SO Majekodunmi (647_CR27) 2020; 3
A Kordjamshidi (647_CR56) 2019; 45
647_CR4
N Eizadi-Mood (647_CR19) 2014; 5
C Gérardin (647_CR25) 2013; 42
B Bameri (647_CR40) 2018; 37
647_CR10
KL Cumpston (647_CR21) 2018; 5
RB Raffa (647_CR45) 2008; 325
L Ventura (647_CR11) 2018; 11
MP Cuajungco (647_CR52) 1997; 4
M Mabrouk (647_CR28) 2021; 109
EA Salem (647_CR6) 2007; 177
S Babalonis (647_CR36) 2013; 129
V Jovanović-Čupić (647_CR35) 2006; 44
References_xml – ident: 647_CR30
  doi: 10.15171/apb.2019.013
– volume: 109
  start-page: 1029
  year: 2021
  ident: 647_CR28
  publication-title: J Biomed Mater Res B Appl Biomater
  doi: 10.1002/jbm.b.34767
  contributor:
    fullname: M Mabrouk
– volume: 310
  start-page: 108
  year: 2016
  ident: 647_CR38
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2016.09.013
  contributor:
    fullname: C Lagard
– volume: 129
  start-page: 116
  year: 2013
  ident: 647_CR36
  publication-title: Drug Alcohol Depend
  doi: 10.1016/j.drugalcdep.2012.09.018
  contributor:
    fullname: S Babalonis
– volume: 4
  start-page: 137
  year: 1997
  ident: 647_CR52
  publication-title: Neurobiol Dis
  doi: 10.1006/nbdi.1997.0163
  contributor:
    fullname: MP Cuajungco
– ident: 647_CR24
  doi: 10.1248/cpb.44.1361
– volume: 93
  start-page: 1534
  year: 2015
  ident: 647_CR50
  publication-title: J Neurosci Res
  doi: 10.1002/jnr.23609
  contributor:
    fullname: T Alexa
– volume: 445
  start-page: 42
  year: 2008
  ident: 647_CR51
  publication-title: Neurosci Lett
  doi: 10.1016/j.neulet.2008.08.081
  contributor:
    fullname: Y Song
– ident: 647_CR31
  doi: 10.1007/s42411-018-0010-7
– volume: 142
  start-page: 729
  year: 2021
  ident: 647_CR55
  publication-title: Acta Neuropathol (Berl)
  doi: 10.1007/s00401-021-02348-6
  contributor:
    fullname: TS Zimmer
– volume: 33
  start-page: 75
  year: 2018
  ident: 647_CR16
  publication-title: Drug Metab Pers Ther
  doi: 10.1515/dmpt-2017-0040
  contributor:
    fullname: M Ahmadimanesh
– volume: 27
  start-page: 928
  year: 2010
  ident: 647_CR46
  publication-title: Emerg Med J
  doi: 10.1136/emj.2009.083162
  contributor:
    fullname: H Saidi
– volume: 27
  start-page: 9721
  year: 2007
  ident: 647_CR43
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.2993-07.2007
  contributor:
    fullname: M Miura
– volume: 10
  start-page: 432
  year: 2004
  ident: 647_CR47
  publication-title: Neuroscientist
  doi: 10.1177/1073858404263463
  contributor:
    fullname: TG Smart
– volume: 5
  start-page: 301
  year: 2018
  ident: 647_CR21
  publication-title: Curr Treat Options Psychiatry
  doi: 10.1007/s40501-018-0149-x
  contributor:
    fullname: KL Cumpston
– volume: 31
  start-page: 1325
  year: 2015
  ident: 647_CR20
  publication-title: Toxicol Ind Health
  doi: 10.1177/0748233713491814
  contributor:
    fullname: TM Mohamed
– volume: 69
  start-page: 568
  year: 2018
  ident: 647_CR34
  publication-title: Brain Behav Immun
  doi: 10.1016/j.bbi.2018.02.004
  contributor:
    fullname: W Zhu
– volume: 11
  start-page: 97
  year: 2018
  ident: 647_CR11
  publication-title: Curr Mol Pharmacol
  doi: 10.2174/1874467210666170704110146
  contributor:
    fullname: L Ventura
– volume: 5
  start-page: 63
  year: 2009
  ident: 647_CR13
  publication-title: J Med Toxicol
  doi: 10.1007/BF03161089
  contributor:
    fullname: H Talaie
– volume: 117
  start-page: 90
  year: 2015
  ident: 647_CR33
  publication-title: Epilepsy Res
  doi: 10.1016/j.eplepsyres.2015.09.008
  contributor:
    fullname: KD Phelan
– ident: 647_CR23
  doi: 10.1680/cc.25929
– volume: 45
  start-page: 14126
  year: 2019
  ident: 647_CR56
  publication-title: Ceram Int
  doi: 10.1016/j.ceramint.2019.04.113
  contributor:
    fullname: A Kordjamshidi
– volume: 131
  start-page: 1382.e1
  year: 2018
  ident: 647_CR44
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2018.04.025
  contributor:
    fullname: S Hassamal
– volume: 52
  start-page: 629
  year: 2014
  ident: 647_CR15
  publication-title: Clin Toxicol
  doi: 10.3109/15563650.2014.918627
  contributor:
    fullname: C Reichert
– volume: 18
  start-page: 395
  year: 2015
  ident: 647_CR2
  publication-title: Pain Physician
  doi: 10.36076/ppj.2015/18/395
  contributor:
    fullname: AD Kaye
– volume: 325
  start-page: 500
  year: 2008
  ident: 647_CR45
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.108.137273
  contributor:
    fullname: RB Raffa
– volume: 39
  start-page: 175
  year: 2007
  ident: 647_CR32
  publication-title: Behav Res Methods
  doi: 10.3758/BF03193146
  contributor:
    fullname: F Faul
– volume: 3
  start-page: 1
  year: 2020
  ident: 647_CR27
  publication-title: Int Res J Pharm Med Sci
  contributor:
    fullname: SO Majekodunmi
– volume: 31
  start-page: 145
  year: 1989
  ident: 647_CR48
  publication-title: Int Rev Neurobiol
  doi: 10.1016/S0074-7742(08)60279-2
  contributor:
    fullname: CJ Frederickson
– volume: 111
  start-page: 133
  year: 2012
  ident: 647_CR18
  publication-title: Basic Clin Pharmacol Toxicol
  doi: 10.1111/j.1742-7843.2012.00874.x
  contributor:
    fullname: S Shadnia
– volume: 34
  start-page: 97
  year: 2013
  ident: 647_CR5
  publication-title: Subst Abuse
  doi: 10.1080/08897077.2012.677752
  contributor:
    fullname: E Hamdi
– volume: 7
  start-page: 307
  year: 2006
  ident: 647_CR53
  publication-title: Biogerontology
  doi: 10.1007/s10522-006-9045-7
  contributor:
    fullname: V Frazzini
– volume: 46
  start-page: 6581
  year: 2020
  ident: 647_CR26
  publication-title: Ceram Int
  doi: 10.1016/j.ceramint.2019.11.144
  contributor:
    fullname: MA Mahdy
– volume: 20
  start-page: 1423
  year: 2000
  ident: 647_CR8
  publication-title: Pharmacother J Hum Pharmacol Drug Ther
  doi: 10.1592/phco.20.19.1423.34854
  contributor:
    fullname: JS Gardner
– volume: 53
  start-page: 545
  year: 2015
  ident: 647_CR9
  publication-title: Clin Toxicol Phila Pa
  doi: 10.3109/15563650.2015.1036279
  contributor:
    fullname: NM Ryan
– volume: 5
  start-page: 302
  year: 2014
  ident: 647_CR19
  publication-title: Int J Prev Med
  contributor:
    fullname: N Eizadi-Mood
– volume: 56
  start-page: 737
  year: 2018
  ident: 647_CR39
  publication-title: Clin Toxicol
  doi: 10.1080/15563650.2017.1401080
  contributor:
    fullname: C Lagard
– volume: 41
  start-page: 206
  year: 2015
  ident: 647_CR1
  publication-title: Am J Drug Alcohol Abuse
  doi: 10.3109/00952990.2015.1014959
  contributor:
    fullname: MM Bassiony
– volume: 67
  start-page: 433
  year: 2016
  ident: 647_CR41
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-062613-093100
  contributor:
    fullname: C Stein
– ident: 647_CR22
  doi: 10.1016/B978-0-7216-0693-4.50007-4
– volume: 42
  start-page: 4217
  year: 2013
  ident: 647_CR25
  publication-title: Chem Soc Rev
  doi: 10.1039/c3cs35451b
  contributor:
    fullname: C Gérardin
– volume: 131
  start-page: 203
  year: 2000
  ident: 647_CR42
  publication-title: Br J Pharmacol
  doi: 10.1038/sj.bjp.0703562
  contributor:
    fullname: H Potschka
– volume: 21
  start-page: 148
  year: 2014
  ident: 647_CR7
  publication-title: Middle East Curr Psychiatry
  doi: 10.1097/01.XME.0000449839.69324.71
  contributor:
    fullname: MA El-Hadidy
– volume: 79
  start-page: 122
  year: 2020
  ident: 647_CR17
  publication-title: Neurotoxicology
  doi: 10.1016/j.neuro.2020.05.002
  contributor:
    fullname: RM Shamloul
– volume: 9
  start-page: 175909141774652
  year: 2017
  ident: 647_CR54
  publication-title: ASN Neuro
  doi: 10.1177/1759091417746521
  contributor:
    fullname: M Rudy
– volume: 37
  start-page: 164
  year: 2018
  ident: 647_CR40
  publication-title: Int J Toxicol
  doi: 10.1177/1091581817753607
  contributor:
    fullname: B Bameri
– volume: 3
  start-page: 484
  year: 2012
  ident: 647_CR14
  publication-title: Casp J Intern Med
  contributor:
    fullname: R Boostani
– volume: 177
  start-page: 345
  year: 2007
  ident: 647_CR6
  publication-title: J Urol
  doi: 10.1016/S0022-5347(18)31271-0
  contributor:
    fullname: EA Salem
– volume: 111
  start-page: 981
  year: 2007
  ident: 647_CR49
  publication-title: Rev Med Chir Soc Med Nat Iasi
  contributor:
    fullname: D Ciubotariu
– volume: 44
  start-page: 143
  year: 2006
  ident: 647_CR35
  publication-title: Clin Toxicol
  doi: 10.1080/1556365050014418
  contributor:
    fullname: V Jovanović-Čupić
– volume: 48
  start-page: 7218
  year: 2022
  ident: 647_CR29
  publication-title: Ceram Int
  doi: 10.1016/j.ceramint.2021.11.282
  contributor:
    fullname: MA Mahdy
– volume: 134
  start-page: 57
  year: 2003
  ident: 647_CR37
  publication-title: Forensic Sci Int
  doi: 10.1016/S0379-0738(03)00100-2
  contributor:
    fullname: F Clarot
– volume: 1
  start-page: 52
  year: 2019
  ident: 647_CR3
  publication-title: J Illicit Econ Dev
  doi: 10.31389/jied.10
  contributor:
    fullname: A Klein
– ident: 647_CR4
– ident: 647_CR10
  doi: 10.1172/JCI43195
– volume: 3
  start-page: 15
  year: 2007
  ident: 647_CR12
  publication-title: J Med Toxicol
  doi: 10.1007/BF03161033
  contributor:
    fullname: JG Thundiyil
SSID ssj0000778852
Score 2.3157022
Snippet Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the drug-induced...
Background Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the...
BackgroundSeizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the...
BACKGROUNDSeizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the...
Abstract Background Seizures are considered to be the most common symptom encountered in emergency- rushed tramadol-poisoned patients; accounting for 8% of the...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 9
SubjectTerms Acute intoxication
Adsorption
Analgesics, Opioid - adverse effects
Animals
Antidote
Benzodiazepines
Calcium
Calcium Compounds
Calcium oxide
Calcium silicates
Composite materials
Convulsions & seizures
Detoxification
Diazepam
Drug delivery systems
Drug dosages
Ferric oxide
Hematite
Intoxication
Iron compounds
Iron oxides
Laboratory animals
Mice
Nano-microstructure
Nitrates
Scanning electron microscopy
Seizures
Seizures (Medicine)
Seizures - chemically induced
Seizures - drug therapy
Silica
Silicate phases
Toxicity
Toxicity management
Tramadol
Wollastonite
Zinc oxide
Zinc Oxide - toxicity
Zinc oxides
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hnrggHgUChboSKgdq1evHJjmWiqpCAu2hlSoulmM7IodmK3Yj0X_PjJ3dbsSBCznGY8mZ90QznwE-CBr_KBvH0fc5rl2pucNIxt0M_aSXoY6Ofuh_-z6_vNZfb8zNzlVf1BOW4YEz406dCN6gz2xrbTRW3A4jfKOM8K41mEtknE8hd4qp5INLLO2M3EzJVPPTlUZfLTiGKJ4GLLmYRKIE2P-3W96JS9OeyZ0gdPEUnozZIzvLp34Gj2L_HI4XGX76_oRdPUxTrU7YMVs8AFPfv4DFj673bPm7C5GhaHw33LJVl6fgGPWWUwNXZIS42Q-UgzLnB3yBJ7kl5Ce2xr0e03bW9Yyusd-H64svV-eXfLxRgXtT6zUP7SyGWawwh_FlUI1Tuq50jUWNpwvHMP1p5mFWRiwqqUmqar3yIZrglRAR96iXsNcv-_gamFRRYvATpsUAh2lO0zRGitY7qnl1UAV82nDX3mXgDJsKjmpusywsysImWVhRwGcSwJaSQK_TC1QFO6qC_ZcqFHBI4rN5gnRruvasVJiHKjxkAR8TBRkv8s67cQYBP4lgsCaUBxNKNDo_Xd6oiB2NfmVliU8lqlIWcLRdpp3UyNbH5ZBoTKrBTQGvskZtP1ph8Vaj0y-gnOjahCvTlb77mSDBMcuX6Enf_A82voXHMpmJ5KI-gL31ryG-w8xr3bxPRvYH0M8oYA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZge-GCeBMoYCRUDtSq48cmOaEWtaqQqFaolSoulmM7kEOT0mwk-u-ZcbLZRkjsMR5rHY9n5htnHoR84Jj-kZWWge6zTNlMMQuWjNkU9KQTvggWL_S_nS1PL9TXS305Xrh1Y1jlRidGRe1bh3fkByKDX87zTHy-_s2waxR-XR1baNwnOyKVeb4gO0fHZ6vv0y0Lhzm5FptsmXx50CnQ2ZyBqWIx0ZLxmUWKhfv_Vc937NM8dvKOMTp5RB6OKJIeDmx_TO6F5gnZWw1lqG_36fk2q6rbp3t0tS1QffuUrH7UjaPtn9oHCixydX9Fu3rIhqMYY46BXIFi5c2mRyxKrevhAazkCitA0TXMdQDfad1QbGf_jFycHJ9_OWVjZwXmdKHWzFdp8GnIAcu4zMvSSlXkqgDnxmHjMYBB5dKnWQDnEoOl8spJ54P2TnIeYI58ThZN24SXhAoZBBhBriswdAB3yrLUglfOou-rvEzIp83umuuhgIaJjke-NAMvDPDCRF4YnpAjZMBEicWv44P25qcZZclY7p0GM1oVSqu0UBZAXyk1d7bSAC_hL98h-8yQSTqJsDnMJOBRCYtMyMdIgUIMe-fsmIsAr4TlsGaUuzNKED43H94cETMKf2e2RzUh76dhnIkBbU1o-0ijoy-uE_JiOFHTS0tw4gpQ_gnJZmdttivzkab-FUuDA9oXoFFf_X9Zr8kDEQVAMF7sksX6pg9vAFuty7ejAP0FxggifA
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Lb9MwHLamceGCeBMYYCQ0Dszg-NEkB4QGYpqQhnpYpYmL5TgORGLp1jbS-t_z2Um7RexCj4ndJv69vq_6PQh5y0P5R1ZaBt9nmbKZYhaRjNkUftKJqvA2_KF_8mNyPFPfz_TZDtmMOxoOcHkrtQvzpGaLPx-uLtefYfCfosHnk49LBTfMGaIPi7WTDBT-jkBkDCleJwPcj545A-GLQ3gE12BNABubOppbv2YUq2JL_38d943INc6qvBGmju6TewO-pIe9QjwgO759SPanfYPq9QE9va63Wh7QfTq9bl29fkSmP5vW0flVU3kK4bmmO6fLpq-ToyH7PKR4eRp6crZdQKnUug4X8CTnoTcUXWGvA7CnTUvDoPvHZHb07fTrMRtmLjCnC7ViVZ36KvU5UI7LKllaqYpcFaA9LowkA0AqJ1WaedDOkEaV1066yuvKSc499sgnZLedt_4ZoUJ6gfDIdY0QCCBUlqUWvHY2sGJVyYS835yuuehba5hISfKJ6WVhIAsTZWF4Qr4EAWxXhrbY8cJ88csMVmYsr5xGgK0LpVVaKAs4WErNna01gCd-8nUQn-lrTLfGbQ4zCaQq8ZAJeRdXBIXD2Tk7VCnglUKjrNHKvdFKmKUb396oiNlotREZPjnPM5GQN9vbYWdIdWv9vItrdGTpOiFPe43avrQEvSsQFhKSjXRtdCrjO23zOzYNBw8Q8LXP_-vQX5C7ItqDYLzYI7urRedfAoStylfRsv4C_DYprw
  priority: 102
  providerName: Scholars Portal
Title Zinc oxide calcium silicate composite attenuates acute tramadol toxicity in mice
URI https://www.ncbi.nlm.nih.gov/pubmed/36759887
https://www.proquest.com/docview/2777780872
https://search.proquest.com/docview/2775614465
https://pubmed.ncbi.nlm.nih.gov/PMC9912638
https://doaj.org/article/a0dc5299f9454194a514b350caf51633
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9swFBdtd9ll7HveukyD0R1WNbI-IvuYlpYSSDFbC2EXIctyZ1ic0sSw_vd7ku00Zrfl4ID1hGW9r98z7z0h9IX68g-VGwK2zxBhlCAGPBkxMdhJy4rUGf9Bf341ubwRs4Vc7CHZ18KEpH2bVyf17-VJXf0KuZV3Szvu88TG2fwMMA0DuRnvo31wvzshejC_CqI6yfoCmWQyXgsw05SAdyKhtpL44984IOU0ZNLt-KPQtv9f47zjnYaZkzuu6OI5etZhSDxt1_oC7bn6JTrK2ibUD8f4-rGman2Mj3D22J764RXKfla1xas_VeEwMMhWzRKvq7YWDvsMc5_G5bDvu1k3HoliYxu4AStZ-v5PeANzLYB3XNXYH2b_Gt1cnF-fXZLuXAViZSo2pChjV8QuASRjVcFzw0WaiBRCG-uPHQMQlE-KWDkILX2qVFJabgsnC8spdTCHv0EH9ap27xBm3DFwgVSW4OYA7OR5LhktrfGRryh4hL71u6vv2vYZOoQdyUS3bNHAFh3YommETj0DtpS-9XW4sbq_1Z0AaEMLK8GJlqmQIk6FAciXc0mtKSWAS3jkJ88-3daRbhVYTxUHNMphkRH6Gii8CsPeWdNVIsAr-WZYA8rDASWonh0O9yKiO9Vfa6bgl9BEsQh93g77mT6drXarJtDIEInLCL1tJWr70r1gRkgNZG2wK8MR0JPQGLzTi_f_PfMDesqCmjBC00N0sLlv3EcAXZt8BKq2UCP0ZDqd_ZjB_-n5VfZ9FD5hwHUuklFQw7-OHS_v
link.rule.ids 230,314,727,780,784,864,885,2102,12056,21388,24318,27924,27925,31719,31720,33744,33745,43310,43805,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELege4CXie9lDGYkNB6YNTe2m-QJbWhTga2qUCdNvFiO7UAelo6lkdh_z52TpouQ6GN8Vh2f7-53zn0Q8p5j-keSGwa6zzBpEskMWDJmxqAnbewyb_BC_2I2mV7Kr1fqqrtwq7uwyrVODIraLS3ekR_FCfxSnibxp5vfDLtG4dfVroXGQ7KFldPViGydnM7m3_tbFg5zUhWvs2XSyVEtQWdzBqaKhURLxgcWKRTu_1c937NPw9jJe8bo7AnZ7lAkPW7Z_pQ88NUzcjBvy1DfHdLFJquqPqQHdL4pUH33nMx_lJWlyz-l8xRYZMvmmtZlmw1HMcYcA7k8xcqbVYNYlBrbwANYyTVWgKIrmGsBvtOyotjO_gW5PDtdfJ6yrrMCsyqTK-aKsXdjnwKWsYkTuREyS2UGzo3FxmMAg_KJGycenEsMlkoLK6zzylnBuYc54iUZVcvK7xAaCx-DEeSqAEMHcCfPcxXzwhr0faUTEfm43l190xbQ0MHxSCe65YUGXujAC80jcoIM6Cmx-HV4sLz9qTtZ0oY7q8CMFplUcpxJA6AvF4pbUyiAl_CX-8g-3WaS9iKsjxMBeFTAIiPyIVCgEMPeWdPlIsArYTmsAeXegBKEzw6H10dEd8Jf681Rjci7fhhnYkBb5ZdNoFHBF1cRedWeqP6lBThxGSj_iCSDszbYleFIVf4KpcEB7cegUXf_v6x98mi6uDjX519m316Tx3EQhpjxbI-MVreNfwM4a5W_7YTpL3yMJWQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagSIgLYm-gUCOhcqBuHC-T5FgKo7K0yqGVKi6WYzsQicmMOhOJ_nuenWSaiBtzjJ81jt_2vegtCL2jvvwjLTUB26eJ0KkgGjwZ0QnYScNs7rT_oH92Pju9FF-v5NVo1FdI2jdlfdT8Xhw19a-QW7lamHjIE4uLsxPANAzkJl7ZKr6L7kkOQjYK1IMRTiG2k2wok8lm8VqAsaYEfBQJFZbED4HjgJfzkE838kqhef-_Jnrko6b5kyOHNH-EHvZIEh93J36M7rjmCTooulbUN4f44rayan2ID3Bx26T65ikqftSNwcs_tXUY2GTqdoHXdVcRh32euU_mcth332xaj0exNi08gJMsfBcovIG9BiA8rhvsR9o_Q5fzzxcnp6SfrkCMzMWG2CpxNnEZ4BmTWl5qLvJM5BDgGD98DKBQObNJ6iDA9AlTWWW4sU5awyl1sIc_RzvNsnG7CDPuGDhCKitwdgB5yrKUjFZG-_hXWB6hD8PtqlXXREOF4CObqY4tCtiiAlsUjdBHz4AtpW-AHR4sr3-qXgyUptZIcKVVLqRIcqEB-JVcUqMrCRAT_nLfs0911aRbNVbHKQdMyuGQEXofKLwiw90Z3dcjwCv5llgTyr0JJSigmS4PIqJ6A7BWLIVfRrOURejtdtnv9EltjVu2gUaGeFxG6EUnUduXHgQzQulE1ia3Ml0BbQntwXvtePnfO_fR_eLTXH3_cv7tFXrAgsYwQvM9tLO5bt1rQGGb8k3Qt7-r1i57
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Zinc+oxide+calcium+silicate+composite+attenuates+acute+tramadol+toxicity+in+mice&rft.jtitle=BMC+pharmacology+%26+toxicology&rft.au=ElShebiney%2C+Shaimaa+A.&rft.au=Elgohary%2C+Rania&rft.au=Kenawy%2C+Sayed+H.&rft.au=El-Bassyouni%2C+Gehan+T.&rft.date=2023-02-09&rft.issn=2050-6511&rft.eissn=2050-6511&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs40360-023-00647-0&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s40360_023_00647_0
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-6511&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-6511&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-6511&client=summon